TBL2 Antibody

Basic Research Questions

How to validate TBL2 antibody specificity in breast cancer research models?

• Methodological approach:

  • Perform knockdown/knockout controls using siRNA or CRISPR in cell lines (e.g., MDA-MB-231) to confirm loss of signal in Western blot (WB) and immunohistochemistry (IHC) .

  • Use cross-species validation (human, mouse, rat) as described in reactivity profiles , but verify with species-specific blocking peptides.

  • Combine with proteomic validation (e.g., IP-MS) to confirm interactions with known partners like PRMT5/WDR77, as demonstrated in BC studies .

What are optimal experimental conditions for TBL2 detection in formalin-fixed paraffin-embedded (FFPE) tissues?

• Protocol optimization:

  • Antigen retrieval: Use citrate buffer (pH 6.0) at 95°C for 20 min.

  • Antibody dilution: Start with 1:200–1:500 for IHC, validated in BC patient cohorts with high TBL2 expression .

  • Signal validation: Compare with mRNA levels (RT-qPCR) from adjacent tissue sections to confirm protein-mRNA correlation .

Advanced Research Questions

How to resolve contradictory data on TBL2’s role in AKT activation across cancer types?

• Analytical framework:

  • Context-dependent analysis:

    • In breast cancer, TBL2 scaffolds PRMT5/WDR77 to enhance AKT phosphorylation .

    • Compare with bladder cancer models where TBL2 may regulate lipid metabolism instead .

  • Pathway inhibition assays:

    Condition	AKT Phosphorylation	Proliferation
    TBL2 knockdown	↓ 60%	↓ 45%
    PRMT5 inhibitor	↓ 75%	↓ 70%
    Data derived from BC cell line studies

What strategies address nonspecific binding in co-immunoprecipitation (co-IP) using TBL2 antibodies?

• Technical solutions:

  • Pre-clearing: Use protein A/G beads with lysate pre-incubation to reduce nonspecific interactions.

  • Competition assays: Include excess recombinant TBL2 protein (50–100 µg/mL) to block antibody binding .

  • Cross-validation: Confirm interactions with orthogonal methods (e.g., PLA assay or split-luciferase systems) .

Data Interpretation & Troubleshooting

How to interpret heterogeneous TBL2 expression patterns in BC patient cohorts?

• Statistical guidelines:

  • Subgroup stratification: Correlate IHC scores (H-score) with clinical parameters (T-stage, recurrence) using multivariate Cox regression .

  • Threshold definition: Classify "high TBL2" as ≥30% tumor cells with moderate-to-strong staining, linked to reduced RFS (P = 0.003) and OS (P = 0.023) .

Can TBL2 antibodies distinguish between isoforms or post-translational modifications?

• Limitations and solutions:

  • Current commercial antibodies (e.g., AF9209) target the N-terminal WD40 domain, which is conserved across isoforms .

  • For PTM studies:

    • Use Phos-tag gels to detect phosphorylation.

    • Combine with glycosidase treatment (e.g., PNGase F) to assess glycosylation status.

Comparative Antibody Performance